ESR1 and invasive breast carcinoma: Raloxifene, a selective estrogen receptor modulator, preserves bone mass and decreases vertebral fractures but not non-vertebral fractures; although raloxifene displays extra-skeletal benefits such as favorable effects on the lipid profile and risk of invasive breast cancer, it might worsen hot flashes, carries an estrogen-like risk of venous thrombosis, and increases the risk of death from stroke in women with cardiovascular risk factors [6,46].